Dual Chamber Prefilled Syringes Market: Safety Prefilled Syringes will Account for nearly 30% of Revenue Share – Scrutinized Report by Fact.MR

The mass technological transformation of the global healthcare industry has left key market participants struggling to traverse the complexities of medical and life sciences. Given the shifting dynamics of the global healthcare sector, pharma and biotech companies are taking measured efforts to improve patient outcomes in an effective manner, while keeping a careful watch on the bottom line.

According to Fact.MR’s recently collated research report, a spectacular growth has been envisaged for the global dual chamber prefilled syringes market in the forecast period (2017-2026). Worldwide sales of dual chamber prefilled syringes are poised to bring in approximately US$ 3,300 Mn revenues by 2026-end.

For more insights, Request a Sample of Tricuspid Valve Repair Market Report

https://www.factmr.com/connectus/sample?flag=S&rep_id=486

Dual Chamber Prefilled Syringes – Efficient Solution for Reconstituting Lyophilized Drugs during Administration

There has been an incessant requirement for reconstituting the lyophilized drugs during their administration, along with the growing necessity of tackling potential compliance and safety issues associated with the reconstitution. This has further led to the development of syringes that are capable of curtailing a number of steps required for the reconstitution of drugs and making them available for injection. Dual chamber prefilled syringes are the most efficient solution to cater to this requirement, as they enable immediate reconstitution within the syringe just prior to injection. Dual chamber prefilled syringes seek widespread utilization in storing biological substances and active pharmaceutical components, which cannot retain their stability for an extended duration. These devices enable the elimination of drug loss through maintenance of the drugs’ sterility prior to injection. Advancements in technology have resulted in improvements in the arrangement of liquid components in the syringes and injectors while attracting more patients in opting for these efficient & safe syringes.

Lyophilized drugs have represented a robust penetration worldwide in the recent past. Lyophilized drugs account for the largest share of all reconstitution-requiring injectable/infusible drugs. As a large number of injectable/infusible drugs have been developed for self-administration, special challenges are incurred for the drug developers. However, dual chamber prefilled syringes, which are particularly designed for simplifying reconstitution devoid of patient handling of diluent or drug, have become the mainstay option for delivering these drugs, meanwhile curtailing challenges faced by developers. With lyophilized drugs witnessing proliferated penetration, demand for dual chamber prefilled syringes will gain a significant upsurge in the foreseeable future.

Market Taxonomy

Region Product Type Product Material Sales Channel
North America Conventional Prefilled Syringes Glass Prefilled Syringes Hospital Pharmacies
Latin America Safety Prefilled Syringes Plastic Prefilled Syringes Retail Pharmacies
Europe Online Pharmacies
Japan
APEJ
MEA

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

 

For comprehensive insights on this market adoption, ask an analyst here

https://www.factmr.com/connectus/sample?flag=AE&rep_id=486

 

5 Key Takeaways from Fact.MR’s Report on Dual Chamber Prefilled Syringes Market for Forecast Period 2017-2026

  • Sales of dual chamber prefilled syringes are expected to record the fastest expansion in online pharmacies through 2026, trailed by retail pharmacies that will account for a relatively larger market revenue share than online pharmacies by 2026-end.
  • In terms of revenues, hospital pharmacies will continue to be the leading contributor to the global dual chamber prefilled syringes market.
  • Based on product material, glass prefilled syringes are anticipated to remain sought-after in the market, with sales projected to exceed US$ 2,000 Mn in revenues by 2026-end. Plastic prefilled syringes will exhibit a relatively higher CAGR in the market through 2026.
  • On the basis of product type, conventional prefilled syringes are expected to account for the lion’s share of the market from 2017 to 2026. Safety prefilled syringes will account for nearly 30% revenue share of the market through the forecast period.
  • North America is likely to prevail as the fast-expanding as well as the most lucrative market for dual chamber prefilled syringes, followed by Europe. Asia-Pacific excluding Japan (APEJ) will also account for a major chunk of the market’s revenue share during the forecast period.

With trends of surging demand for self-injection syringes and the development of advanced dual chamber prefilled syringes, major players in the market have directed their concentration toward product portfolio expansion. In this rapidly evolving and highly competitive market, several players are emphasizing on the essentiality of the up-to-date information, in a bid to monitor their performance and make critical decisions apropos to profitability & growth. Few market players are also focusing on improvements in the design of the dual chamber prefilled syringes in order to enhance the stability as well as safety of various sensitive drugs. Key players actively underpinning the market growth, as profiled by Fact.MR’s report, include Pfizer Inc., Amgen Inc., Boehringer Ingelheim GmbH, Nipro Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, Gerresheimer AG, Ypsomed Holding AG, West Pharmaceutical Services, Inc., Schott AG, Otsuka America Pharmaceutical, Inc., Credence MedSystems, Inc., Catalent, Inc., and Bespak Europe Ltd.

Explore Fact.MR’s Coverage on the Healthcare Domain

Auto Disable Syringes Market: A recent study by Fact.MR on the Auto Disable Syringes Market offers a 10-year forecast analysis for the period 2018 to 2028. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Chromatography Syringes Market: Fact.MR’s extensive coverage on the chromatography syringes market offers in-depth insights into the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Syringe Market: The Syringe Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities, and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in the United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Research Insight:  https://www.factmr.com/report/486/dual-chamber-prefilled-syringes-market

Content Source: https://www.factmr.com/media-release/425/dual-chamber-prefilled-syringes-market

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: sales@factmr.com

Visit Our Website: https://www.factmr.com

SourceFACT.MR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”